EXPERIENCE OF IBRUTINIB THERAPY IN THE TREATMENT OF PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA
https://doi.org/10.18821/0234-5730-2017-62-1-55-56
Abstract
There is a necessity for effective drugs in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treatment that would not worsen the patients quality of life. Clinical case of a patient with chemoresistant CLL, who got Ibrutinib treatment, is discussed. The drug has a fairly quick response, high efficiency efficacy and emissionslow toxicity. Of particular interest are rare side effects detected while therapy and require correction doses of the drug.
About the Authors
N. V. Kurkina
National Research Mordovian State University n.a. N.P. Ogarev; Republican Clinical Hospital № 4
Russian Federation
Kurkina Nadezhda V., MD, PhD, associate professor Medical Institute of National Research Mordovian State University n.a. N.P. Ogarev, Saransk, 430032
Russian Federation
Kurkina Nadezhda V., MD, PhD, associate professor Medical Institute of National Research Mordovian State University n.a. N.P. Ogarev, Saransk, 430032
E. A. Repina
National Research Mordovian State University n.a. N.P. Ogarev
Russian Federation
Saransk, 430032
Russian Federation
Saransk, 430032
N. N. Mashnina
Republican Clinical Hospital № 4
Russian Federation
Saransk, 430032
Russian Federation
Saransk, 430032
References
1. Byrd J., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2013; 369(1): 32–42. doi: 10.1056/NEJMoa1215637.
2. Kil L.P., de Bruijn M.J., van Hulst J.A., Langerak A.W., Yuvaraj S., Hendriks R.W. Bruton’s tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am. J. Blood Res. 2013; 3(1): 71–83.
3. Cheson B.D., Byrd J.C., Rai K.R., Kay N.E., O’Brien S.M., Flinn I.W., et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J. Clin. Oncol. 2012; 30(23): 2820–2. doi:10.1200/JCO.2012.43.3748
4. Byrd J.C., Furman R.R., Coutre S.E., Burger J.A., Blum K.A., Coleman M., et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015; 125(16): 2497–506. doi: 10.1182/blood-2014-10-606038.
5. Byrd J.C., Brown J.R., O’Brien S., Barrientos J.C., Kay N.E., Reddy N.M., et al.; RESONATE Investigators. Ibrutinib versus Ofatumumab in previously treated chronic lymphoid leukemia N. Engl. J. Med. 2014; 371(3): 213–23. doi: 10.1056/NEJMoa1400376.
6. Savchenko V. G., ed. Programs of treatment of diseases of the blood system: the Collection of diagnostic algorithms and protocols for the treatment of diseases of the blood system. Moscow: Practice; 2012. (in Russian)
7. Imbruvica TM summary of product characteristics. Janssen-Cilag International NV. 2014. Instructions for use of the drug for medical use, Imbruvika. 11. Access 06.2016. Available: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=18e07787-d116-4d56-9583-82c26fef9993&t=
8. Chavez J., Sahakian E., Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid. 2013; 8: 37–45. doi: 10.2147/CE.S34068.
Review
For citations:
Kurkina N.V., Repina E.A., Mashnina N.N. EXPERIENCE OF IBRUTINIB THERAPY IN THE TREATMENT OF PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA. Russian journal of hematology and transfusiology. 2017;62(1):55-56. (In Russ.) https://doi.org/10.18821/0234-5730-2017-62-1-55-56
Views:
681
Email this article 
